Lv1
40 积分 2021-06-12 加入
Efficacy and safety of complement inhibitors and FcRn blockers in generalized AChR antibody-positive myasthenia gravis: a meta-analysis
1个月前
已完结
Efgartigimod in Patients with Generalized Myasthenia Gravis Refractory or Intolerant to IVIg
1个月前
已完结
Double‐Filtration Plasmapheresis Versus Efgartigimod for Generalized Myasthenia Gravis: Severity‐Stratified Benefits in a Prospective Observational Multicenter Study
2个月前
已完结
The Fiscal Consequences for the Canadian Government of Efgartigimod in the Treatment of Generalized Myasthenia Gravis
2个月前
已关闭
Who Can Safely Discontinue Treatment in Myasthenia Gravis? Insights From a Long-Term Real-World Study
2个月前
已完结
Safety and Effectiveness of Eculizumab in Patients With Refractory Ocular or Ocular‐Predominant Myasthenia Gravis: A Case Series
2个月前
已完结
Zilucoplan is effective for ravulizumab-refractory generalized myasthenia gravis with the C5 p.Arg885His variant: a case report
2个月前
已完结
MuSK autoantibodies in myasthenia gravis detected by cell based assay — A multinational study
2个月前
已完结
Safety and efficacy of zilucoplan in patients with generalised myasthenia gravis (RAISE): a randomised, double-blind, placebo-controlled, phase 3 study
2个月前
已完结
Influence of Efgartigimod on Curative Efficacy and Inflammation Factors of Patients with Long Segmental Myelitis
3个月前
已关闭
皖公网安备34019202002308
